Focal boosted IMRT treatment of prostate cancer to 84 Gy in 28 fractions: preliminary clinical outcomes, toxicity, and dosimetry
A novel 28-fraction focal boosted IMRT treatment is feasible and has an acceptable preliminary toxicity profile. Oncologic results are promising but require longer follow up and prospective study.
Authors
- Fayez Estephan
- Ramez Andrawis (ORCID: https://orcid.org/0000-0002-6202-5049)
- M. Ojong-Ntui
- Harold A. Frazier (ORCID: https://orcid.org/0000-0002-2435-9013)
- Shawn Haji-Momenian (ORCID: https://orcid.org/0000-0002-6236-4956)
- Destie Provenzano (ORCID: https://orcid.org/0000-0002-7470-4604)
- Yuan James Rao (ORCID: https://orcid.org/0000-0002-9938-2197)
- Michael J. Whalen (ORCID: https://orcid.org/0000-0002-2423-072X)
- Hamid Aghdam
- Sharad Goyal (ORCID: https://orcid.org/0000-0002-6475-7411)
- Julie E. Bauman (ORCID: https://orcid.org/0000-0002-1398-6636)
- J.M. Hands
- Dongjun Chen
Institutions
- George Washington University Hospital (US)
- George Washington University (US)
- Washington University Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.3389/fonc.2025.1577359
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00